ESR1 and breast cancer: In ER-positive/PR-negative luminal B-like breast cancer cells, however, FASN signaling might be co-opted as a negative regulator of the epithelial cell phenotype and, accordingly, its blockade might promote the restoration and activation of prolactin/PRLR-driven differentiation programs.